

### REMARKS

The Communication asserts that a copy of the Sequence Listing in computer readable form has not been submitted. Applicants have amended the application to include an updated Sequence Listing which contains the nucleotide and/or amino acid sequences disclosed in the application. New pages 1-28 are provided to comply with the Sequence Rules set forth in 37 C.F.R. §§ 1.821-1.825. Applicants also submit; a computer readable form (CRF) copy of the Sequence Listing, a Statement to Support the filing of the Sequence Listing. No new matter has been added.

An executed Declaration of the inventors is submitted herewith. No new matter has been added.

Figures 11 and 15 were inadvertently omitted from the application as filed. This application benefits from priority to PCT/US2004/013379 filed April 4, 2005, which benefits from priority to nonprovisional application, US Serial No. 10/454,663, filed June 4, 2003, which are incorporated by reference in its entirety. The inadvertently omitted drawings are contained in prior-filed application US Serial No. 10/454,663. Applicant herewith submits figures 11 and 15 to be entered into the record of the subject application pursuant to 37 CFR § 1.57. No new matter has been added.

The amendments to the specification at page 7 merely clarify that nucleic acid sequences found in Figures 1-3 are also provided in the sequence listing. No new matter has been added.

The amendment to the specification at page 94 merely corrects the sequence listing identifier for GenBank Accession Number J03132.1 from SEQ ID NO: 90 to SEQ ID NO:138 and corrects designation ICAM\_1 to ICAM-1. No new matter has been added.

Entry of the foregoing amendments and remarks into the record for the subject application is respectfully requested.

**FEEs**

Applicants herewith submit the \$130.00 late declaration surcharge and \$520 application size fee for 64 additional pages. It is believed that no additional fee is due with this response. If an additional fee is due, the Commissioner is hereby authorized to charge deposit account 50-0252 referencing docket ISPH-0852USA.

Respectfully submitted,

Date: 9/11/08

Teresa Y. Liang  
Teresa Y. Liang, Ph.D.  
Registration No. 51,946

Isis Pharmaceuticals  
1896 Rutherford Road  
Carlsbad, CA 92008  
Telephone: (760) 603-4601